BNTX - InSysBio partners with Genmab in solid tumours

InSysBio collaborates with Genmab ([[GMAB]] -8.8%) for GEN1042, a bispecific agonistic antibody for solid tumors.The key aim of this collaboration is to develop a quantitative system pharmacology ((QSP)) model that allows exploration of the relationships between dose, schedule, and tumor response in patients treated with this novel agent. Moreover, InSysBio has developed internal tools and software facilitating the process of model development.Genmab and BioNTech ([[BNTX]] -2.9%) are jointly developing GEN1042 using the DuoBody technology.

For further details see:

InSysBio partners with Genmab in solid tumours